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Abstract
Purpose: To assess the predictive value of volumetric apparent diffusion coefficient (vADC) histogram quantification
obtained before and 6 weeks (6w) post-treatment for assessment of hepatocellular carcinoma (HCC) response to
90Yttrium radioembolization (RE).
Methods: In this retrospective study, 22 patients (M/F 15/7, mean age 65y) who underwent lobar RE were included
between October 2013 and November 2014. All patients underwent routine liver MRI pre-treatment and 6w after
RE. Two readers assessed index tumor response at 6 months after RE in consensus, using mRECIST criteria. vADC
histogram parameters of index tumors at baseline and 6w, and changes in vADC (ΔvADC) histogram parameters
were calculated. The predictive value of ADC metrics was assessed by logistic regression with stepwise parameter
selection and ROC analyses.
Results: Twenty two HCC lesions (mean size 3.9 ± 2.9 cm, range 1.2–12.3 cm) were assessed. Response at 6 months
was as follows: complete response (CR, n = 6), partial response (PR, n = 3), stable disease (SD, n = 12) and
progression (PD, n = 1). vADC median/mode at 6w (1.81–1.82 vs. 1.29–1.35 × 10− 3 mm2/s) and ΔvADC median/max
(27–44% vs. 0–10%) were significantly higher in CR/PR vs. SD/PD (p = 0.011–0.036), while there was no significant
difference at baseline. Logistic regression identified vADC median at 6w as an independent predictor of response
(CR/PR) with odds ratio (OR) of 3.304 (95% CI: 1.099–9.928, p = 0.033) and AUC of 0.77. ΔvADC mean was identified
as an independent predictor of CR with OR of 4.153 (95%CI: 1.229–14.031, p = 0.022) and AUC of 0.91.
Conclusion: Diffusion histogram parameters obtained at 6w and early changes in ADC from baseline are predictive
of subsequent response of HCCs treated with RE, while pre-treatment vADC histogram parameters are not. These
results need confirmation in a larger study.
Trial registration: This retrospective study was IRB-approved and the requirement for informed consent was
waived.
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Background
Hepatocellular carcinoma (HCC) is the 6th most
common malignancy and the second most common
cause of cancer-related mortality worldwide [1]. Radical
treatment options including liver transplantation and
surgical resection are available only in a small number of
cases with HCC. Liver transplantation is usually
performed in patients with cirrhosis and HCC within
the Milan criteria [2]. Owing to limited availability of
donor organs the waiting time prolongs and thus in-
creases the chance of dropout due to tumor progression
[3]. 90Yttrium radioembolization (RE) has been demon-
strated to be safe and effective [4, 5] and can be used for
downstaging or bridging of patients listed for liver
transplantation [6–8]. Therefore, the evaluation of tumor
response after RE is essential in directing clinical
management, for indication of repeat treatment and
prognostication.
The modified Response Evaluation Criteria in Solid
Tumors (mRECIST), using the single largest diameter of
the arterially hyperenhancing viable tumor, is currently
proposed as the standard methodology to assess
radiological response in HCC [9]. mRECIST is primarily
based on contrast-enhanced computed tomography
(CT) or T1-weighted imaging (CE-T1WI) with magnetic
resonance imaging (MRI). Although mRECIST has been
shown to predict survival post transarterial chemoembo-
lization (TACE) [10–14], a unified consensus on an early
imaging biomarker to assess HCC tumor response and
outcome post RE has not been reached.
Diffusion-weighted imaging (DWI) provides informa-
tion on cell membrane integrity and cellular density.
Several studies have suggested that apparent diffusion
coefficient (ADC) is an earlier surrogate of response
compared to size criteria in HCC treated by RE [15–18].
Kamel et al. [19–24] first developed the use of volumet-
ric ADC (vADC) in this setting. A survival benefit was
demonstrated in cholangiocarcinoma and neuroendo-
crine liver metastases treated by TACE exhibiting
response by vADC [19, 23, 24]. One of these studies
focused on the identification of volumetric functional re-
sponse criteria of HCC treated by TACE and confirmed
that vADC potentially enables patient stratification for
survival [19, 21]. To the best of our knowledge, there is
only one study exploring the use of vADC in HCC post
RE, in which the authors concluded that vADC
performed better than RECIST in detecting response
using liver explant as the reference, without being able
to predict complete pathological necrosis [25].
First order radiomics features (histogram analysis)
assess the spectrum of ADC values obtained from all
voxels within a volume of interest. The information
about the distribution of ADC values within the tumor
can offer valuable additional insights into tumor
structure and heterogeneity [26–33]. This information
could be of benefit in predicting response and prognosis
in HCC post RE.
The aim of our preliminary study was to assess the
predictive value of histogram quantification measured
on vADC obtained before and at 6 weeks (6w) post-
treatment for assessing HCC response to RE as assessed
by mRECIST criteria at 6 months (6 m).
Material and methods
Patients
This retrospective study was IRB-approved and the
requirement for informed consent was waived. Our
institutional database was queried between October
2013 and November 2014, to identify patients who had
HCC and underwent MRI before and after RE. Fifty five
patients were identified. Thirty three patients were
excluded for the following reasons: previous RE (n = 12),
previous TACE (n = 1), no follow-up imaging/CT follow-
up at 6w or 6 m (n = 9), and different b-values for the
DWI acquisitions at baseline and 6w (n = 11). The final
study group comprised 22 patients (M/F 15/7, mean age
65y). Diagnosis of HCC was based on OPTN criteria
[34] (n = 17) or tissue sampling (n = 5). Five patients had
a histologically proven moderately differentiated HCC.
Fifteen patients underwent lobar RE of the right lobe
and 7 patients of the left lobe. The exclusive lobar RE
treatment reflects our initial experience with RE, which
now has evolved to more segmental treatments. All
patients had cirrhosis, with the following etiologies:
chronic hepatitis C (n = 14), chronic hepatitis B (n = 3),
nonalcoholic steatohepatitis (n = 3), alcohol abuse (n = 1)
or cryptogenic cirrhosis (n = 1). The median alpha-
fetoprotein (AFP) before RE was 22.9 and after RE 10
ng/ml. Patient’s characteristics are given in Table 1.
MRI acquisition
Imaging was performed with different clinical systems
(baseline, 6w and 6m): 3 T GE 750 (n = 10), 1.5 T GE
Signa (n = 17), 3 T Siemens Skyra (n = 11) or 1.5 T
Siemens Aera (n = 28). Routine liver MRI protocol
included non-fat suppressed axial and coronal single-
shot fast spin-echo T2-weighted imaging (WI) (HASTE/
SSFSE), axial fat suppressed fast spin echo (FSE) T2WI,
T1WI in- and out-of- phase, diffusion-weighted imaging
and dynamic contrast-enhanced (CE)-T1WI including
image subtraction.
For dynamic CE-T1WI, unenhanced, early (AP1) and
late arterial phases (AP2), portal venous phase (PVP)
(60s), transitional phase (TP) (180 s), and hepatobiliary
phase (HBP) (at 10 and 20 min) were obtained using a
3D T1WI breath-hold fat-suppressed spoiled gradient-
recall echo sequence (VIBE or LAVA) before and after
administration of gadoxetic acid disodium (Primovist/
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Eovist, Bayer HealthCare). A fixed dose of 10 ml of
contrast (mean weight-based dose of 0.03 mmol/kg) was
injected at a rate of 1.5 ml/s followed by a 20ml saline
flush using a bolus tracking method.
DWI was performed in the axial plane with tri-
directional diffusion gradients using 3 b-values (50, 400,
and 800 s/mm2). DWI was acquired after contrast
administration. Previous studies have shown that there
is no significant difference in the ADC values of focal
hepatic lesions before and after administration of
gadolinium contrast [35, 36]. ADC maps using a mono-
exponential diffusion model with the 3 b-values were
automatically generated from the MRI systems. Accept-
able interplatform reproducibility in ADC values has
been reported, including between 1.5 T and 3 T systems
[37–41]. Recently, we have reported excellent inter-
platform reproducibility (1.5 T vs 3 T) of ADC using a
dedicated DWI phantom (coefficient of variation CV
< 7%), as well as in healthy volunteers (CV < 13.5%) [39].
Image analysis
Lesion selection
The study coordinator (MW, with 5 years of experience
in abdominal MRI) reviewed clinical data, and images
using a PACS, and identified the largest index tumor
that underwent RE. If multiple lesions were present in
the same lobe, only the largest HCC (≥ 1 cm) was
assessed. Size, segment location, series number(s) and
image number(s) where the lesion was visualized on the
6 m follow-up imaging and was recorded for each HCC
to ensure that the readers analyzing the data assessed
the same lesions. Anonymized evaluation sheets, provid-
ing this information, were given to the two observers
who analyzed the images qualitatively and quantitatively.
Qualitative image analysis
Two observers (SG, and CB, with 2 and 5 years of
experience in abdominal MRI, respectively) reviewed the
images at baseline, 6w and 6m in consensus in random
order, and assessed mRECIST (in cm) on native,
contrast-enhanced and subtracted T1W images at 6 m
follow-up MRI on the index lesions. Both observers were
informed of the presence and location of HCCs, but they
were blinded to clinical data and ADC values.
Quantitative image analysis
All series, including ADC maps, of each baseline and 6w
follow-up MRI scans were transferred to a workstation
equipped with a dedicated software (OsiriX, Bernex,
Switzerland) permitting volumetric tumor delineation
and data analysis. One observer (SG, with 2 years of
experience in abdominal MRI) performed the quantita-
tive analysis 6w after the qualitative image analysis to
decrease recall bias. Freehand regions of interest (ROIs)
were placed on the whole index tumors, including nec-
rotic portions. Volumes of interest (VOIs) were acquired
by drawing ROIs on each slice of the ADC map where
the tumor was delineated. Tumor size was measured on
the axial post-contrast T1-weighted arterial phase or
portal venous images. Volumetric tumor delineation on
ADC was aided by registering to other DWI and CE-
T1WI, and by delineating areas suspicious of tumor
(diffusion restriction, arterial enhancement). All scanner
generated ADC maps and ROIs at baseline and 6w
follow-up of each patient were exported and tumor
volume and vADC histogram parameters (mean, median,
mode, min, max, kurtosis and skewness) were calculated
subsequently using a MATLAB script (The Mathworks,
Inc., Natick, MA).
ΔvADC was measured as : ΔvADC %ð Þ
¼ vADC 6w  vADC baselineð Þ=vADC baseline½ 
 100:
Reference standard
The reference standard was defined as response of the
target lesion at 6 months as assessed by mRECIST [9]: 1)
complete response (CR): disappearance of intratumoral
arterial hyperenhancement in target lesion; 2) partial re-
sponse (PR): ≥ 30% decrease in the sum of diameter of
viable (intratumoral arterial hyperenhancement) target
lesion; 3) stable disease (SD): no qualification for PR or
PD; 4) progressive disease (PD): ≥ 20% increase in the
Table 1 Population characteristics
Variable N %
Age 65 ± 6
Sex (M/F) 15/7 68/32
Etiology of liver disease
Chronic HCV 14 64
Chronic HBV 3 14
NASH 3 14
Alcohol abuse 1 4
Cryptogenic 1 4
Alpha-fetoprotein
Pre-treatment [median (range), ng/ml] 22.95 (0.9–11.309)
Post-treatment [median (range), ng/ml] 10 (2.4–31.813)
Child-Pugh Score A/B/C 19/3/0 86/14/0
Radiation dose [mean ± SD, GBq] 2.1 ± 1.5
Time between pre-treatment MRI and RE
[mean ± SD, days]
60 ± 22
Time between radioembolization and
6w follow-up imaging [mean ± SD, days]
57 ± 21
Time between RE and follow-up MRI
[mean ± SD, days]
137 ± 41
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sum of diameters of viable (intratumoral arterial hyper-
enhancement) target lesion.
Statistical analysis
Quantitative variables were expressed as mean ± stand-
ard deviation and categorical variables as frequencies or
percentages. A Mann-Whitney U test was used to test
for significant differences between AFP, vADC mean,
median, mode, min, max, kurtosis and skewness at
baseline and 6w. A multivariable logistic regression ana-
lysis with stepwise parameter selection using Wald tests
was used to test imaging variables (baseline ADC, ADC
6w and ΔvADC), lesion size (diameter and volume) and
AFP values as predictors of any tumor response (partial
response/ complete response) and complete response in
the index lesion at 6 months. Prior to regression analysis,
parameters were standardized to have zero mean and
unit standard deviation. Receiver operating characteris-
tics (ROC) analysis was performed for the parameters
selected by the logistic regression procedure to assess
the utility of the measures for the detection of response
at 6 months. All statistical analyses were conducted
using SPSS software (release 21.0; SPSS, Chicago, Il). A
two-tailed p-value less than 0.05 was considered to
indicate a significant difference.
Results
Twenty-two HCC lesions with a mean diameter of 3.9 ±
2.9 cm (range 1.2–12.3 cm) were assessed in 22 patients.
Fifteen lesions were located in the right hepatic lobe and
7 in the left hepatic lobe. The response at 6 m was as
follows: 6 tumors with complete response (CR, 27.2%), 3
tumors with partial response (PR, 13.6%), 12 tumors
with stable disease (SD, 54.6%) and 1 tumor with
progression (PD, 4.6%).
Quantitative analysis
Pre- and post-treatment serum AFP levels were not
significantly different in patients with PR/CR vs. those
with SD/PD (p = 0.456 and p = 0.554, respectively). No
significant difference was observed in tumor size and
volume in patients with PR/CR and SD/PD at baseline
and at 6w (Table 2). There was no significant difference
in pre-treatment vADC parameters between patients
with PR/CR vs. those with SD/PD, while vADC median
and mode were significantly higher at 6w in patients
with PR/CR vs. those with SD/PD. Furthermore, ΔvADC
median and ΔvADC max were found to be significantly
higher in patients with PR/CR vs. those with SD/PD
(Table 2, Fig. 1).
Using a multivariable logistic regression analysis with
stepwise parameter selection, we identified vADC
median at 6w as an independent predictor of any re-
sponse [PR/CR; odds ratio (OR) 3.304, p = 0.033)], while
ΔvADC mean was identified as an independent pre-
dictor of CR (OR 4.153, p = 0.022). A vADC median
threshold of 1.901 × 10− 3 mm2/s at 6w had a sensitivity
of 67% and a specificity of 100% for prediction of PR/
CR, while a ΔvADC mean threshold of 19.2% had a
sensitivity of 100% and a specificity of 81% for prediction
of CR (Table 3, Figs. 1, 2).
Discussion
In this preliminary study, we have evaluated the poten-
tial of vADC histogram measurements obtained pre-
and early (6w) post-treatment for prediction of HCC
response to RE. Volumetric histogram parameters vADC
median, mode, ΔvADC median and ΔvADC max
obtained at 6w post-treatment were significantly differ-
ent between patients with PR/CR vs. those with SD/PD.
Furthermore, ΔvADC mean was an independent pre-
dictor of complete response at 6 m, while vADC median
Table 2 Volumetric ADC histogram measurements (vADC) obtained at baseline and 6 weeks (6w) post 90Yttrium radioembolization
in index tumors, as well as differences between baseline and 6w
Baseline 6w Δ (%)
PR/CR SD/PD p PR/CR SD/PD p PR/CR SD/PD p
Maximum diameter (cm) 3.02 ± 1.08 4.55 ± 3.61 0.65 4.11 ± 2.56 4.25 ± 3.43 0.56 61.7 ± 172.9 −4.1 ± 12.1 0.47
Volume (cm3) 19.75 ± 29.78 176.29 ± 345.45 0.33 12.84 ± 22.02 149.67 ± 308.98 0.27 153.3 ± 286.2 140.7 ± 308.7 0.54
vADC mean (10− 3 mm2/s) 1.34 ± 0.49 1.27 ± 0.22 0.85 1.82 ± 0.48 1.36 ± 0.26 0.06 43.3 ± 40.1 8.3 ± 21.5 0.05
vADC median (10−3 mm2/s) 1.35 ± 0.52 1.25 ± 0.22 1 1.82 ± 0.47 1.35 ± 0.25 0.04 43.6 ± 41.2 10.3 ± 20.9 0.04
vADC mode (10−3 mm2/s) 1.36 ± 0.66 1.06 ± 0.39 0.21 1.81 ± 0.45 1.29 ± 0.30 0.02 46.1 ± 45.2 108.1 ± 336.7 0.19
vADC min (10−3 mm2/s) 0.67 ± 0.31 0.67 ± 0.36 0.39 1.21 ± 0.57 0.83 ± 0.44 0.13 118.2 ± 166.2 80.9 ± 240.6 0.24
vADC max (10−3 mm2/s) 2.00 ± 0.56 2.32 ± 0.85 0.43 2.46 ± 0.55 2.25 ± 0.80 0.51 27.2 ± 32.2 −0.0 ± 27.8 0.01
vADC kurtosis 3.32 ± 1.13 4.53 ± 3.00 0.26 3.18 ± 0.57 4.05 ± 1.73 0.43 8.5 ± 47.1 −2.3 ± 33.6 0.79
vADC skewness 0.38 ± 0.48 0.66 ± 0.57 0.24 −0.03 ± 0.53 0.35 ± 0.54 0.16 − 141.3 ± 120.2 −125.6 ± 142.1 0.56
PR partial response, CR complete response, SD stable disease, PD progressive disease
Significant p-values are bolded
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was an independent predictor of any response (partial
and complete) at 6 m. Pre-treatment vADC did not have
any predictive value for response at 6 m.
mRECIST is currently proposed as the standard
method to assess radiological response of HCC [9] and
has been shown to predict survival in patients with HCC
post TACE [10–13]. However, a unified consensus on an
early imaging biomarker to assess HCC tumor response
and outcome post RE has not been reached.
Two MRI-pathological correlation studies [42, 43]
from the same group of investigators showed poten-
tial of the World Health Organization (WHO) and
the European Association for the Study of the Liver
(EASL) criteria to predict complete pathological
necrosis in patients with HCC post-RE. Such correl-
ation was not observed in patients with HCC post
RE ± sorafenib in a recent study [44] by the same
group.
DWI provides information on cell membrane integrity
and cellular density. Several studies have suggested that
ADC can be used as earlier surrogate of response com-
pared to size criteria in HCC treated by RE [15–17].
Kokabi et al. [45] reported that ADC measured at 30
days in 18 patients post RE was able to predict HCC
response at 3 months with a sensitivity of 90%. A >
30% increase in ADC value at 30 days, furthermore,
predicted significantly prolonged survival. Also, Nie-
kamp et al. [46] showed that a pre-procedure ADC <
1.01 × 10− 3 mm2/s is an independent predictor of
poorer immediate complete or partial response and
index lesion specific progression free survival in pa-
tients with HCC undergoing TACE or RE. The dis-
crepancy with our results may be due to different
locoregional therapies (TACE+RE in their study vs.
RE only in our study). On the other hand, Vouche
et al. [44], however, observed no significant change in
ADC at baseline, 1 and 3 months in patients with
HCC post RE ± sorafenib. Furthermore, ADC was not
able to predict complete pathological necrosis in their
MRI-pathological study including 15 patients.
Recent studies demonstrated ADC changes in the
index tumor volume rather than in a single axial plane
[19, 24]. A survival benefit was shown in cholangiocarci-
noma and neuroendocrine liver metastases treated by
TACE exhibiting response by vADC [19, 23, 24].
Bonekamp et al. [19] reported that volumetric func-
tional (vADC and volumetric enhancement) response
3-4w after TACE in patients with HCC showed im-
proved overall survival and was superior to current
imaging response criteria (RECIST, mRECIST, and
EASL) and AFP [19]. Chapiro et al. [22] found that
vADC alone correlated strongly with tumor necrosis
at pathologic examination in patients with HCC post
TACE.
There is limited data on the role of vADC in HCC
post RE, with only one study from Vouche et al. [25].
The authors showed that vADC (mean and standard de-
viation) significantly increased 4w post RE in 21 patients
with HCC and performed better than RECIST in
Fig. 1 63-year-old male patient with HCV cirrhosis and HCC treated
with radioembolization (RE). Pre-treatment MRI: HCC (arrows)
demonstrates restricted diffusion with high signal on high b value
DWI (b 800) (a) and low ADC on ADC map (b). Post-treatment MRI
at 6w post RE shows resolution of diffusion restriction on DWI (b 800)
(c) with residual low ADC areas in tumor (d). Contrast-enhanced-
T1weighted images obtained during the portal-venous phase at
baseline (e) and 6months (f) show complete tumor response at 6
months. Corresponding histogram distribution of vADC at baseline
(blue, vADC median 1.08 × 10− 3 mm2/s, vADC mean 1.07 × 10− 3 mm2/s)
and 6w after RE (red, vADC median 1.91 × 10− 3 mm2/s, vADC mean
1.89 × 10− 3 mm2/s, ΔvADC median 78%, ΔvADC mean 76%) shows a
shift of the distribution to the right after RE (g)
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detecting image response post RE using liver explant
as reference. However, vADC was not able to predict
complete pathological necrosis. They reported vADC
(mm2/s × 10− 3) mean and standard deviation (SD)
values of 0.185 and 0.041 at baseline and 1.91 and
0.201 at 4 weeks. In line with their results we ob-
served a significant increase in vADC 6w post RE,
however our vADC mean and SD values were higher
with 1.288 and 0.325 mm2/s × 10− 3 at baseline and
1.534 and 0.423 mm2/s × 10− 3 at 6w. An explanation
might be related to differences in b-values used for
DWI acquisition (0, 500/50, 500/50, 500, 1000 and
50, 500, 800 in their study vs. 50, 400 and 800 s/mm2
in our study).
Most prior studies have reported mean ADC values
from a single slice, which do not account for the
underlying tumor heterogeneity. Histogram analysis
(i.e. first order radiomics) is a new approach for
quantifying tumor heterogeneity using routine MRI
data. Radiomics, which is defined as the conversion
of images to higher-dimensional data and the subse-
quent mining of these data for improved decision
support, appears to offer a nearly limitless supply of
imaging biomarkers that could potentially aid cancer
detection, diagnosis, assessment of prognosis, predic-
tion of response to treatment, and monitoring of dis-
ease status [47]. Histogram analysis refers to a
mathematical approach to evaluate gray-level inten-
sity variations within a VOI and may be used to as-
sess intralesional heterogeneity [33]. Studies on
different tumors showed that MR histogram analysis
could be helpful for diagnosis, biologic aggressiveness
evaluation, and therapy response prediction [28–32].
Hu et al. [26] correlated vADC parameters with Ki-
67 labeling index in patients with HCC. They found
that vADC mean, median 5th, 25th and 75th percen-
tiles demonstrated significant inverse correlations
with Ki-67 labeling index. Moriya et al. [27] corre-
lated vADC parameters with histologic grade of
HCC. They reported that vADC min showed signifi-
cant differences among tumor histological grades.
ADC min of poorly differentiated HCC was
significantly lower than that of combined well and
moderately differentiated HCC.
The assessment of treatment response with imaging
techniques plays a critical role in the management of
HCC. Tumor response criteria may be used as a sur-
rogate marker of efficacy in clinical trials in HCC,
and as predictors of survival following RE. It has been
suggested that DWI is an earlier surrogate of re-
sponse compared to size criteria in HCC treated by
RE [15–17]. vADC measurements, as early as 3–4
weeks post transarterial chemoembolization, have
shown promising results in predicting survival [19]
and treatment response [20, 22] in patients with HCC
post TACE. Our results suggest that changes in
vADC histogram measurements at 6w post RE consti-
tute potential early biomarkers of subsequent treat-
ment response. Future work should include a larger
sample size, and should evaluate second order radio-
mics texture features on DWI and other sequences
such as dynamic T1-weighted imaging. Furthermore,
inter-platform variability of radiomics features should
be assessed.
Our study had several limitations. First, this was a
retrospective study. Second, our study population was
slightly underpowered showing an overall power of 75%
for presence of type II error (false negative rate), reflect-
ing our preliminary experience. Third, the qualitative
image analysis was performed by two readers in consen-
sus, which precluded the evaluation of interobserver
variability. Interobserver reproducibility for mRECIST
was shown to be excellent (ICC of 0.77–0.84) in a recent
publication [14]. Fourth, we used enhancement change
as surrogate endpoint and did not have histopathological
proof of tumor necrosis or data on patient survival.
Fifth, we used only one index lesion to classify the re-
sponse, even though some patients had a large disease
burden that may have required response assessment of
the entire intrahepatic tumor volume. Sixth, we used
different MRI systems and field strengths in our
study. However, acceptable inter-platform reproduci-
bility in ADC values has been reported by us and
other groups [37–41].
Table 3 Logistic regression with stepwise selection of parameters for prediction of response (PR/CR and CR)
Parameter Logistic regression ROC analysis
OR (CI95%) p AUC p Threshold Sensitivity (%) Specificity (%)
PR/CR
vADC median 6w (10−3 mm2/s) 3.304 (1.099–9.928) 0.033 0.77 (0.53–1.00) 0.035 1.901 66.7 100.0
CR
ΔvADC mean (%) 4.153 (1.229–14.031) 0.022 0.91 (0.78–1.00) 0.004 19.2 100.0 81.3
AUC area under the curve, CR complete response, OR odds ratio, PR partial response
Results of logistic regression and ROC analysis of the parameters selected by the logistic regression procedure are shown
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Conclusion
Our preliminary results indicate that volumetric ADC
measurements obtained at 6 weeks and early changes in
ADC from baseline are predictive of subsequent re-
sponse in HCCs treated with RE, while pre-treatment
vADC did not have any predictive value.
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